The inflammatory bowel diseases (IBD), Crohn's disease (CD), and ulcerative colitis (UC),
Introduction
Crohn's disease (CD) and ulcerative colitis (UC) are the two major clinical forms of inflammatory bowel disease (IBD), and the actual combined prevalence is 150-200 per 100 000 in Europe and North America. 1, 2 The pathogenesis of IBD is still unknown, but epidemiological data from family studies and twin studies strongly implicate a genetic susceptibility. [3] [4] [5] The current concept is that of a complex multifactorial trait involving both environmental and genetic factors. Identification of IBD susceptibility genes would represent a major advance in the understanding of these diseases.
Mannan-binding lectin (MBL) is a serum lectin which binds with high affinity to mannose and N-acetylglucosamine terminated glycoproteins on microbial surfaces, and is capable of activating the complement pathway independent of antibody through the lectin pathway. 6, 7 Through its intrinsic ability to opsonize and mediate phagocytosis, MBL plays an important role in first-line defense. 8 Three different point mutations with a dominant effect on serum MBL concentration have been identified in codons 52, 54 and 57 of exon 1 of the MBL gene. All three variants impede the assembly of MBL subunits into the basic trimer structure, reduce the activity of the protein through local structural changes and/or make the subunits more vulnerable to degradation. This results in a reduction of the amount of functional serum MBL, which in turn leads to a defect of opsonization and increased susceptibility to various infectious diseases. [9] [10] [11] [12] [13] Several pathogenic organisms have been implicated in the pathogenesis of IBD, the most important ones being Mycobacterium paratuberculosis, Listeria monocytogenes and measles virus. [14] [15] [16] Given the importance of MBL in the immune response against microorganisms, 17, 18 MBL could be an important factor in the protection against these putative etiological microbial agents in IBD. Furthermore, in patients with Crohn's disease a significant rise of antiglycan antibodies to the cell wall mannan of Saccharomyces cerevisiae (ASCA) has been shown and is currently used as a diagnostic tool. 19, 20 If these antibodies should reflect the presence of an infectious microbial agent, a possible role of MBL in the immune response against this organism should be evaluated.
The potential importance of complement components as inflammatory mediators in IBD emerges from the experimental finding of enhanced local production of complement components and the increased activation of complement in the bowel mucosa of CD patients and UC patients. [21] [22] [23] Given its key role in complement activation through the lectin pathway, MBL could be a contributing factor in this process. It has further been shown that in CD patients and to a lesser degree in UC patients there is an increase in the proportion of oligosaccharide chains on the IgG Fc fragment which terminate with N-acetylglucosamine (GlcNAc) rather than galactose. 24 Aggregated agalactosyl IgG can function as a ligand for MBL, thus initiating complement activation. 25 We have studied the distribution of MBL polymorphisms in IBD patients, their affected and unaffected relatives, and unaffected controls in an attempt to determine whether these MBL mutations influence susceptibility to IBD.
Results

Frequency of MBL mutations in the unaffected control population
The MBL genotype and allele frequencies in the unaffected Flemish control population are given in Table 1 . The allele frequencies for the investigated mutations in the MBL gene are 0.067, 0.143 and 0.021 for codon 52, 54 and 57 respectively. The observed genotype frequencies were in Hardy-Weinberg equilibrium for all three mutations.
Frequency of MBL mutations in IBD patients
MBL allele distributions in the different IBD patient groups and their affected and unaffected relatives are shown in Table 1 . No deviations from expectations under Hardy-Weinberg assumptions were observed.
In the total group of unrelated IBD patients (sporadic . No significant differences in frequency of MBL mutations were found between CD patients and controls, nor between the total group of IBD patients (CD+UC) and controls. Analysis for the different MBL mutations separately also showed no significant differences between CD patients, UC patients and controls. For the codon 54 mutation alone, the allele frequency was lower in the UC group (0.109) when compared to CD patients (0.153), but this difference was below the limit of statistical significance (P = 0.073).
In the group of sporadic IBD patients (n = 340), there were significant differences in MBL genotype distribution between UC and CD patients, and between UC patients and controls. The number of MBL genetic variants was significantly lower in UC patients (36/124, 29.0%) when compared to CD patients (93/216, 43.1%) (P = 0.010) and to controls (126/308, 40.9%) (P = 0.020). In this group, only two UC patients (1.6%) were homozygous or compound heterozygous for the MBL mutations, vs 11 CD patients (5.1%) (P = 0.046) and 16 controls (5.2%) (P = 0.038). The number of MBL heterozygotes was also significantly lower in the UC group (34 or 27.4%) when compared to the CD patients (82 or 38.0%) (P = 0.025), and showed a trend toward lower frequency when compared with the control population (110 or 35.7%) (P = 0.054). Statistical analysis of the frequency of the codon 52, 54 and 57 mutations in the MBL gene separately only showed significant results for the codon 54 mutation. The MBL codon 54 mutation allele frequency was significantly lower in the group of UC patients (0.097) than in the CD patients (0.162) (P = 0.015). Comparison of UC patients with controls (allele frequency 0.143) showed a trend toward a significant difference (P = 0.061). Twenty-three UC patients (18.5%) were variant (= hetero-or homozygote) for the MBL codon 54 mutation, vs 64 CD patients (29.6%) (P = 0.022) and 83 controls (26.9%) (P = 0.061). Similar results were found when comparing the number of codon 54 heterozygotes: 22 (17.7%) UC patients vs 58 (26.9%) CD patients and 78 (25.3%) controls were heterozygous (P = 0.041 and 0.077 respectively). For the codon 57 mutation, we found no homozygotes and only 12 heterozygotes in the complete group of sporadic IBD patients (n = 340). Although the codon 57 mutation frequency was lower in the UC group (1.6% heterozygotes) when compared to CD patients (4.6%) and controls (4.2%), this difference was not statistically significant (P = 0.147 and 0.180 respectively). For the codon 52 mutation, no major differences in mutation frequency were observed between UC patients, CD patients and controls. There were no significant differences in MBL genotype distribution between CD patients and unaffected controls, nor between IBD patients and controls.
Statistical analysis of the MBL genotype distribution among index cases of IBD families showed that in this population, the number of patients with variant MBL genotype was significantly higher among UC patients (12/18, 66.7%) compared to CD patients (29/71, 40.8%) (P = 0.049) and controls (126/308, 40.9%) (P = 0.032).
Comparison of CD patients with controls, and total IBD population with controls showed no significant differences.
Clinical features of IBD patients according to MBL genotype
To assess a possible effect of MBL variance on disease severity, clinical parameters of the IBD patients were analyzed in relation to their MBL genotype (Tables 2a, b, 3a and b). There was no correlation between MBL variance and the age at IBD diagnosis, the frequency of surgical intervention, or disease localization. However, separate analysis of the group of index cases of IBD families showed a significant association between compound het- 
Discussion
MBL most probably has a two-edged role in immunity, and MBL-mutations can therefore function as a mitigating or aggravating factor in inflammatory bowel diseases. Since several pathogenic organisms have been implicated in the pathogenesis of IBD, impairment of the MBLmediated mechanisms of the immune response against these organisms through structural mutations in the MBL gene could well lead to increased IBD susceptibility. By contrast, population studies have revealed unexpectedly high frequencies of structural MBL gene mutations. It has been suggested that this may reflect a selection advantage for reduced activities of MBL-associated immune mechanisms, such that, for example, individuals with lower levels of MBL might be protected against the complement-mediated damage associated with inflammatory diseases. 6, 10 Another hypothesis suggests that MBL mutations, and the resulting MBL protein deficiency, offer protection against infection with intracellular parasites which use C3 opsonization and uptake through C3 receptors to penetrate the host cells, an example being Mycobacterium species, which has previously been suggested as etiological agent in IBD. 26 Both hypotheses concerning a protective role of MBL mutations are not mutually exclusive, and could both apply to the pathogenesis of IBD.
There were no previous reports of allele frequencies for the MBL codon 52, 54 and 57 mutations in a Flemish population. We therefore compared our data with the frequencies determined in other European population groups. The allele frequency for the codon 52 mutation in the MBL gene is 0.067 in our Flemish control population, which is in accordance with frequencies previously determined in smaller study groups from neighboring countries (0.07 in Germany and 0.06 in the U.K.). 18, 27 For the codon 54 point mutation, the allele frequency is 0.143 in our Flemish population, slightly lower than that in 28, 29 The allele frequency for the codon 57 mutation in our control population is 0.021 which is also very similar to frequencies found in northern Europe (0.02 in both Denmark and Norway). 28, 29 In the group of sporadic IBD patients, we found a highly significant decrease in the frequency of MBL variants (ie., the sum of heterozygotes, homozygotes and compound heterozygotes for the three MBL mutations under investigation) among UC patients when compared to CD patients and controls (P = 0.01 and 0.02 respectively), suggesting a protective effect of functional MBL mutations in UC, but not in CD. This could be explained by the differential T-helper (T H ) response in both diseases. Whereas in patients with CD there is selective activation of T H1 -cells, which mainly produce proinflammatory cytokines like interleukin (IL)-2 and interferon (IFN)-␥, UC preferentially brings on a T H2 -response with production of the cytokines IL-4, IL-5, II-6, IL-10 and IL-13. 30, 31 There is in vitro evidence that IL-6 can enhance MBL mRNA expression. 32 MBL could therefore be responsible for more extensive complement-mediated mucosal damage in UC than in CD, and MBL mutations that decrease the expression of functional MBL could protect against the clinical development of UC. Analysis of the codon 54 mutation separately gave similar results: a significant decrease in mutation frequency in the group of sporadic UC patients compared to sporadic CD patients and controls (P = 0.022 and 0.061 respectively). No significant results were found for the codon 52, nor for the codon 57 mutation, when analyzed separately. In case of the codon 57 mutation, this could be explained by the very low allele frequency for this mutation in the normal population (0.021), which results in a low statistical power of the analysis for this mutation. In the complete group of sporadic IBD patients (n = 340), we found no homozygotes for this mutation, and only 12 heterozygotes. Although the codon 57 mutation frequency was lower in the UC group when compared to CD patients and controls, these differences were not statistically significant. For the codon 52 mutation, no major differences in mutation frequency were observed between UC patients, CD patients and controls. A possible explanation for this is that the codon 52 mutation has been shown to have a lesser effect on MBL concentrations than the other two mutations. Whereas the codon 54 and 57 mutations (in which axial glycines are replaced by dicarboxylic acids) disrupt the collagenous Gly-Xaa-Yaa repeat structure within the collagen region of the MBL molecule, which is believed to have a profound effect on the assembly and stability of the triple helix structure of the protein, this is not the case for the codon 52 mutation (a cysteine for arginine substitution). 11, 33 In the small subset of index cases of IBD families (71 CD cases, and only 18 UC cases), by contrast, we found an increase in the number of MBL variants among the UC cases when compared to CD patients (P = 0.048) and controls P = 0.032). Given the rather low number of investigated cases in this subpopulation, the actual effect of MBL mutations in familial IBD remains inconclusive.
We describe, for the first time, an association between mutations in the MBL gene and inflammatory bowel disease. The results of our study support the concept of functional MBL mutations as a protective factor against sporadic ulcerative colitis.
Materials and methods
Subjects
Venous blood samples were obtained from 431 unrelated IBD patients (287 CD, 142 UC, two indeterminate colitis (IC)), their 141 unaffected and 112 affected first-degree relatives. Of these unrelated IBD patients, 91 (21%) had familial IBD with at least two members affected (50 sibling pairs and 41 parent-child affected pairs) and 340 were so-called sporadic IBD cases (only one member affected per family). All patients were seen at the Gastroenterology Unit of the University Hospital Gasthuisberg Leuven. The diagnosis of Crohn's disease and ulcerative colitis was based on the Lennard-Jones criteria. 34 For all patients, full clinical details on age at diagnosis, surgery and localization of disease were obtained. The control population consisted of 308 unselected and unrelated healthy individuals without any familial history of IBD or known immune-mediated disorders. All patients and controls were Caucasians from the region of Flanders, the northern part of Belgium. Ethical approval, based upon the guidelines from the World Medical Association's Declaration of Helsinki, 35 was given by the Ethics Board of the University of Leuven. Informed consent was obtained from all participants.
DNA extraction
DNA was extracted from whole venous blood obtained from the IBD-affected members and their first-degree relatives using a salting-out procedure and stored at −80°C.
36 DNA-samples of the control population were collected through a non-invasive 'swish-and-spit' technique, by rinsing the oral cavity with a 0.9% saline solution, after which genomic DNA was extracted using a simple alkaline lysis procedures.
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Typing of MBL polymorphisms
Three different point mutations in exon 1 of the MBL gene were studied: at codon 52 (CGT→TGT) which results in a change of arginine to cysteine, at codon 54 (GGC → GAC) which results in a change of glycine to aspartic acid, and a codon 57 (GGA → GAA) which results in a change of glycine to glutamic acid.
Detection of the mutations in codon 54 and 57 was performed using polymerase chain reaction (PCR) restriction fragment length polymorphism. 10 A DNA product of 328 bp was made using the forward primer 5Ј-GTAGGA CAGAGGGCATGCTC-3Ј (nucleotides −85 to −66 relative to the first methionine in exon 1 of the MBL gene, GenBank accession number AF080508) and the reverse primer 5Ј-CAGGCAGTTTCCTCTGGAAGG-3Ј (nucleotides 244 to 224). Samples were amplified in a volume of 50 l, with a concentration of 0.1 M of forward and reverse primer, 0. 4 and 6 ). The MBL PCR product (110 bp) is obtained either only with the wild-type primer (if the codon 52 mutation is absent, lanes 1 and 2), only with the mutated primer (if the mutation is present on both alleles, lanes 5 and 6), or with both forward primers (in a heterozygote, lanes 3 and 4). The 238 bp band is the product of an additional pair of primers, which gives amplification of a segment of the CCR5 gene, used as an internal positive control for the PCR reaction. M = size marker (50-bp ladder).
Genes and Immunity
PCR product was digested with 5 units of MboII (MBI Fermentas, Germany) at 37°C for 15 min, followed by a denaturation step at 70°C for 20 min. MboII cleaves the allele with the codon 57 mutation into two fragments (274 and 55 bp), while the wild-type allele remains undigested. Digested fragments were analyzed using polyacrylamide gel electrophoresis and ethidium bromide staining.
The presence of the point mutation at codon 52 of exon 1 of the MBL gene was investigated by amplification refractory mutation system-polymerase chain reaction (ARMS-PCR). For allele-specific amplification of a 110 bp DNA segment of the MBL gene, the oligonucleotides 5Ј-CTTCCCAGGCAAAGACGGGC-3Ј and 5Ј-CTTCCC AGGCAAAGACGGGT-3Ј were used as forward primers for the codon 52 wild-type and mutated allele respectively (nucleotides 135 to 154). Both forward primers contained an additional mismatch at the fifth nucleotide from the 3Ј end (C instead of T) to improve specificity. In both reactions, 5Ј-CAGGCAGTTTCCTCTGGAAGG-3Ј was used as reverse primer (nucleotides 244 to 224). As an internal control for amplification, forward primer 5Ј-GATAGGTACCTGGCTGTCGTCCAT-3Ј
(nucleotides 385 to 408 in the CCR5 gene, GenBank accession number U83326) and reverse primer 5Ј-ACCAGCCCCAAGAT GACTATCT-3Ј (nucleotides 623 to 602), were added to the reaction mixes, giving amplification of a 238 bp segment of the CC-chemokine receptor (CCR) 5 gene. 38 Samples were amplified in a volume of 50 l, with a concentration of 0.2 M of MBL forward and reverse primer, 0.2 M of CCR5 forward and reverse primer, 0.5 mM of nucleotides, 2.5 mM of MgCl 2 and 1 unit of Taq polymerase (Perkin Elmer/Roche Molecular Systems, Belgium) at pH 8.5. Conditions of PCR comprised 5 min denaturation at 95°C, 38 cycles of 40 s at 95°C, 40 s at 64°C and 40 s at 72°C, and 7 min of final elongation at 72°C, in a Geneamp  PCR System 9700 thermal cycler (Perkin Elmer, CA, USA). For homozygotes for the codon 52 wild-type allele, amplification only occurred with the MBL wild-type primer, and for homozygotes for the codon 52 mutation only with the primer that carried the mutation at the 3Ј end, while heterozygotes showed amplification with both primers (Figure 1 ).
All hetero-and homozygotes for the codon 52 mutation, and all homozygotes for the codon 54 and 57 mutation were confirmed by sequencing on an ABI 310 automatic sequencer (Perkin Elmer).
Statistical analysis
The likelihood ratio and Pearson's goodness of fit chisquare tests or, when appropriate, Fisher's exact test were applied to analyze the comparison of the frequency of discrete variables between unrelated IBD patients and unrelated healthy controls. A P-value less than 0.05 was considered to indicate statistical significance.
